43239, a novel GPCR-like molecule and uses thereof

Abstract

Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] The present application is a divisional application of U.S. patent application Ser. No. 09 / 585,876, filed Jun. 1, 2000, which claims the benefit of U.S. Provisional Application No. 60 / 182,061, filed Feb. 11, 2000.FIELD OF THE INVENTION [0002] The invention relates to novel GPCR-like nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules. BACKGROUND OF THE INVENTION [0003] G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell. GPCRs have three structural domains: an amino terminal extracellular domain, a transmembrane domain containing seven transmembrane segments, three extracellular loops, and three intracellular loops, and a carboxyl terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a...

AI Technical Summary

Benefits of technology

[0023] In yet another aspect, the invention provides a method for modulating GPCR-like activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) GPCR-like activity or expression such that GPCR-like activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to GPCR-like protein. In another embodiment, the agent modulates expression of GPCR-like protein by modulating transcription of a GPCR-like gene, splicing of a GPCR-like mRNA, or translation of a GPCR-like mRNA. In yet another embodiment, the agent is a nucleic acid molecule

Problems solved by technology

It has been suggested that when the tumor reaches a size that leads to breakage of cells during abrasive movements, the ATP released acts on nociceptive endings of sensory nerves in the vicinity, resulting in the sensation of pain.

Furthermore, ATP released from damaged muscle following major accidents or surgery could be involved in local pain and in pain associated with traumatic shock.

Images